Evidence map›Paper›PMID 31992186›Full record

ArticleBMC bioinformatics2020

Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches.

Arran K Turnbull, Cigdem Selli, Carlos Martinez-Perez, Anu Fernando, Lorna Renshaw, Jane Keys, Jonine D Figueroa, Xiaping He, Maki Tanioka, Alison F Munro and 8 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in BMC bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Detection ofInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Arran K TurnbullApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.
Cigdem SelliApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.
Carlos Martinez-PerezApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.
Anu FernandoApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.
Lorna RenshawEdinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Jane KeysEdinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Jonine D FigueroaUsher Institute of Population Health Sciences and Informatics, Old Medical School, Teviot Place, Edinburgh, UK.
Xiaping HeLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Maki TaniokaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Alison F MunroApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.
Lee MurphyHost and Tumour Profiling Unit, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Angie FawkesEdinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK.
Richard ClarkEdinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK.
Audrey CouttsEdinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK.
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
J Michael DixonEdinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Andrew H SimsApplied Bioinformatics of Cancer, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK. andrew.sims@ed.ac.uk.ORCID http://orcid.org/0000-0001-9082-3665

Funding

Breast Cancer Institute .Breast Cancer Now .H2020 European Research Council H2020-MSCA-IF, 658170Wellcome TrustWellcome Trust ISSF3
6 · The paper itself

Abstract

backgroundHigh-throughput transcriptomics has matured into a very well established and widely utilised research tool over the last two decades. Clinical datasets generated on a range of different platforms continue to be deposited in public repositories provide an ever-growing, valuable resource for reanalysis. Cost and tissue availability normally preclude processing samples across multiple technologies, making it challenging to directly evaluate performance and whether data from different platforms can be reliably compared or integrated.

methodsThis study describes our experiences of nine new and established mRNA profiling techniques including Lexogen QuantSeq, Qiagen QiaSeq, BioSpyder TempO-Seq, Ion AmpliSeq, Nanostring, Affymetrix Clariom S or U133A, Illumina BeadChip and RNA-seq of formalin-fixed paraffin embedded (FFPE) and fresh frozen (FF) sequential patient-matched breast tumour samples.

resultsThe number of genes represented and reliability varied between the platforms, but overall all methods provided data which were largely comparable. Crucially we found that it is possible to integrate data for combined analyses across FFPE/FF and platforms using established batch correction methods as required to increase cohort sizes. However, some platforms appear to be better suited to FFPE samples, particularly archival material.

conclusionsOverall, we illustrate that technology selection is a balance between required resolution, sample quality, availability and cost.

Indexed as

Gene Expression ProfilingBreast NeoplasmsFemaleFixativesFormaldehydeHumansMicroarray AnalysisParaffin EmbeddingReproducibility of ResultsFixativesFormaldehydeFFPEFresh-frozenGene expressionMicroarraySequencingTranscriptomics

Identifiers

PMID31992186
PMCPMC6988223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.